BACKGROUND: Postoperative stereotactic radiosurgery for brain metastases potentially offers similar local control rates and fewer long-term neurocognitive sequelae compared to whole brain radiation therapy, although patients remain at risk for distant brain failure (DBF). OBJECTIVE: To describe clinical outcomes of adjuvant stereotactic radiosurgery for large brain metastases and identify predictors of intracranial failure and their implications on optimal patient selection criteria. METHODS: We performed a retrospective review on 100 large (>3 cm) brain metastases in 99 patients managed by resection followed by postoperative stereotactic radiosurgery to a median dose of 22 Gy (range, 10-28) in 1 to 5 fractions (median, 3). Primary histology was nonsmall cell lung in 40%, breast cancer in 18%, and melanoma in 17%. Forty (40%) patients had uncontrolled systemic disease. RESULTS: With a median follow-up of 12.2 months (range, 0.6-87.4), the 1-year Kaplan-Meier local control was 72%, DBF 64%, and overall survival 55%. Nine patients (9%) developed evidence of radiation injury, and 6 (6%) developed leptomeningeal disease. Uncontrolled systemic disease (P=.03), melanoma histology (P=.04), and increasing number of brain metastases (P<.001) were significant predictors of DBF on Cox multivariate analysis. Patients with <4 metastases, controlled systemic disease, and nonmelanoma primary (n=47) had a 1-year DBF of 48.6% vs 80.1% for all others (P=.01). CONCLUSION: Postoperative stereotactic radiosurgery to the resection cavity safely and effectively augments local control of large brain metastases. Patients with <4 metastases and controlled systemic disease have significantly lower rates of DBF and are ideal treatment candidates.
BACKGROUND: Postoperative stereotactic radiosurgery for brain metastases potentially offers similar local control rates and fewer long-term neurocognitive sequelae compared to whole brain radiation therapy, although patients remain at risk for distant brain failure (DBF). OBJECTIVE: To describe clinical outcomes of adjuvant stereotactic radiosurgery for large brain metastases and identify predictors of intracranial failure and their implications on optimal patient selection criteria. METHODS: We performed a retrospective review on 100 large (>3 cm) brain metastases in 99 patients managed by resection followed by postoperative stereotactic radiosurgery to a median dose of 22 Gy (range, 10-28) in 1 to 5 fractions (median, 3). Primary histology was nonsmall cell lung in 40%, breast cancer in 18%, and melanoma in 17%. Forty (40%) patients had uncontrolled systemic disease. RESULTS: With a median follow-up of 12.2 months (range, 0.6-87.4), the 1-year Kaplan-Meier local control was 72%, DBF 64%, and overall survival 55%. Nine patients (9%) developed evidence of radiation injury, and 6 (6%) developed leptomeningeal disease. Uncontrolled systemic disease (P=.03), melanoma histology (P=.04), and increasing number of brain metastases (P<.001) were significant predictors of DBF on Cox multivariate analysis. Patients with <4 metastases, controlled systemic disease, and nonmelanoma primary (n=47) had a 1-year DBF of 48.6% vs 80.1% for all others (P=.01). CONCLUSION: Postoperative stereotactic radiosurgery to the resection cavity safely and effectively augments local control of large brain metastases. Patients with <4 metastases and controlled systemic disease have significantly lower rates of DBF and are ideal treatment candidates.
Authors: Chiara Reverberi; Stefania Volpe; Stefano M Magrini; Stefano Arcangeli; Damiano Balestrini; Michela Buglione; Piera Navarria; Silvia Scoccianti; Pierpaolo Panciani; Marco Krengli; Luigi Pirtoli; Lorenzo Bordi; Giovanni L Pappagallo; Rolando M D ' Angelillo Journal: J Cancer Res Clin Oncol Date: 2021-01-23 Impact factor: 4.553
Authors: Hanno M Specht; Kerstin A Kessel; Markus Oechsner; Bernhard Meyer; Claus Zimmer; Stephanie E Combs Journal: Strahlenther Onkol Date: 2016-03-10 Impact factor: 3.621
Authors: John P Kirkpatrick; Scott G Soltys; Simon S Lo; Kathryn Beal; Dennis C Shrieve; Paul D Brown Journal: Neuro Oncol Date: 2017-04-01 Impact factor: 12.300
Authors: Riccardo Soffietti; Ufuk Abacioglu; Brigitta Baumert; Stephanie E Combs; Sara Kinhult; Johan M Kros; Christine Marosi; Philippe Metellus; Alexander Radbruch; Salvador S Villa Freixa; Michael Brada; Carmine M Carapella; Matthias Preusser; Emilie Le Rhun; Roberta Rudà; Joerg C Tonn; Damien C Weber; Michael Weller Journal: Neuro Oncol Date: 2017-02-01 Impact factor: 12.300
Authors: Paul M Foreman; Bradford E Jackson; Karan P Singh; Andrew K Romeo; Barton L Guthrie; Winfield S Fisher; Kristen O Riley; James M Markert; Christopher D Willey; Markus Bredel; John B Fiveash Journal: J Clin Neurosci Date: 2017-12-14 Impact factor: 1.961
Authors: Samuel M Shin; Ralph E Vatner; Moses Tam; John G Golfinos; Ashwatha Narayana; Douglas Kondziolka; Joshua Seth Silverman Journal: Front Oncol Date: 2015-09-22 Impact factor: 6.244
Authors: Jennifer Vogel; Eric Ojerholm; Andrew Hollander; Cynthia Briola; Rob Mooij; Michael Bieda; James Kolker; Suneel Nagda; Geoffrey Geiger; Jay Dorsey; Robert Lustig; Donald M O'Rourke; Steven Brem; John Lee; Michelle Alonso-Basanta Journal: Radiat Oncol Date: 2015-10-31 Impact factor: 3.481
Authors: Federico Pessina; Pierina Navarria; Luca Cozzi; Anna Maria Ascolese; Giulia Maggi; Marco Riva; Giovanna Masci; Giuseppe D'Agostino; Giovanna Finocchiaro; Armando Santoro; Lorenzo Bello; Marta Scorsetti Journal: PLoS One Date: 2016-06-27 Impact factor: 3.240